Address details


Down Syndrome NSW
Level 6/410 Church St, North Parramatta
9am-5pm Monday - Thursday
T: 9841 444


Thursday 4 February 2016

Research news and commentary #2 for 2016


World’s First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer’sDisease-like Characteristics in People with Down Syndrome
AC Immune, 7 January 2016
Today plans were announced to conduct the world’s first clinical trial for a vaccine targeting Alzheimer’s disease-like characteristics in those with Down syndrome. The study will test AC Immune’s vaccine ACI-24 and is being conducted in collaboration with the University of California, San Diego (UC San Diego) Down Syndrome Research and Treatment Center. Funding is provided by a significant grant from the US National Institutes of Health (NIH) and an additional grant from the LuMind Research Down Syndrome Foundation. This is the first public/private collaboration for a clinical trial in the field of Down syndrome ...

Vaccine Targets Alzheimer’s Disease-like Characteristics in People with Down Syndrome
University of San Diego, 13 January 2016
Clinical trial will investigate safety and tolerability of immunotherapy drug to block amyloid buildup in brain ...

Employment model outcomes for people with intellectual disability
The Social Policy Research Centre at the University of NSW is looking for people with intellectual disability, who live in Sydney or the Northern Rivers, to take part in some research about employment.

An Easy English flyer and more details are available on the web page - the information on the website is the same as in the flyer.

Clinical trial gives boy with Down Syndrome new lease on life
WCVB, 3 December 2015
... Jesse was finally breathing on his own through the night, thanks to the implant. No more tubes, no more oxygen, no more sleepless nights for his parents. And finally, no more trach ...
M Stefanini et al, Special Care Dentistry, 29 December 2015
This study demonstrates how the Digital Brush, added to the daily oral hygiene procedures, obtains significant improvements in supragingival plaque control in children with Down syndrome.

No comments: